SLNO · Insider Trading
Soleno Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by SLNO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-18 | Jennifer Fulk | CHIEF FINANCIAL OFFICER | D | −39,200 | — |
| 2026-05-18 | Manher Joshi | Chief Development Officer | D | −20,171 | — |
| 2026-05-18 | Michael F. Huang | Sr. VP of Clinical Development | D | −39,823 | — |
| 2026-05-18 | Mark W Hahn | Director | D | −10,046 | — |
| 2026-05-18 | Matthew Pauls | Director | D | −10,491 | — |
| 2026-05-18 | Meredith Manning | Chief Commercial Officer | D | −64,507 | — |
| 2026-05-18 | Dawn Carter Bir | Director | D | −16,991 | — |
| 2026-05-18 | Kevin Norrett | Chief Business Officer | D | −17,786 | — |
| 2026-05-18 | Bhatnagar Anish | CHIEF EXECUTIVE OFFICER | D | −583,656 | — |
| 2026-05-18 | Andrew Sinclair | Director | D | −10,491 | — |
| 2026-05-18 | Patricia C Hirano | SEE REMARKS | D | −22,702 | — |
| 2026-05-18 | Birgitte Volck | Director | D | −17,536 | — |
| 2026-05-18 | Kristen Yen | SEE REMARKS | D | −37,639 | — |
| 2026-03-04 | Jennifer Fulk | CHIEF FINANCIAL OFFICER | A | +39,200 | — |
| 2026-01-23 | Michael F. Huang | Sr. VP of Clinical Development | A | +10,400 | — |
| 2026-01-23 | Kristen Yen | SEE REMARKS | A | +10,400 | — |
| 2026-01-23 | Kevin Norrett | Chief Business Officer | A | +3,500 | — |
| 2026-01-23 | Bhatnagar Anish | CHIEF EXECUTIVE OFFICER | A | +114,200 | — |
| 2026-01-23 | Patricia C Hirano | SEE REMARKS | A | +10,400 | — |
| 2026-01-23 | Manher Joshi | Chief Development Officer | A | +4,100 | — |
| 2026-01-23 | Meredith Manning | Chief Commercial Officer | A | +28,600 | — |
| 2026-01-23 | James H Mackaness | CHIEF FINANCIAL OFFICER | A | +28,600 | — |
| 2025-12-17 | James H Mackaness | CHIEF FINANCIAL OFFICER | F | −2,013 | −$100.55K |
| 2025-12-17 | Kristen Yen | SEE REMARKS | F | −904 | −$45.15K |
| 2025-12-17 | Michael F. Huang | Sr. VP of Clinical Development | F | −812 | −$40.56K |
| 2025-12-17 | Patricia C Hirano | SEE REMARKS | F | −904 | −$45.15K |
| 2025-12-17 | Meredith Manning | Chief Commercial Officer | F | −1,922 | −$96.00K |
| 2025-12-17 | Bhatnagar Anish | CHIEF EXECUTIVE OFFICER | MIXED | −107,620 | −$380.62K |
| 2025-11-19 | Kevin Norrett | Chief Business Officer | A | +14,286 | — |
| 2025-11-12 | Manher Joshi | Chief Development Officer | A | +16,071 | — |
| 2025-10-14 | Mark W Hahn | Director | A | +10,046 | — |
| 2025-07-03 | Patricia C Hirano | SEE REMARKS | Sell | −3,830 | −$316.97K |
| 2025-06-26 | Patricia C Hirano | SEE REMARKS | MIXED | — | −$10.64K |
| 2025-06-09 | Birgitte Volck | Director | A | +3,991 | — |
| 2025-06-09 | Dawn Carter Bir | Director | A | +3,991 | — |
| 2025-06-09 | William G Harris | Director | A | +3,991 | — |
| 2025-06-09 | Andrew Sinclair | Director | A | +3,991 | — |
| 2025-06-09 | Matthew Pauls | Director | A | +3,991 | — |
| 2025-04-02 | Patricia C Hirano | SEE REMARKS | Sell | −3,782 | −$265.16K |
| 2025-03-31 | Matthew Pauls | Director | MIXED | — | −$397.49K |
| 2025-03-31 | Meredith Manning | Chief Commercial Officer | MIXED | −8,249 | −$1.33M |
| 2025-03-31 | James H Mackaness | CHIEF FINANCIAL OFFICER | MIXED | −20,622 | −$5.47M |
| 2025-03-31 | Patricia C Hirano | SEE REMARKS | MIXED | −81,484 | −$10.10M |
| 2025-03-31 | Kristen Yen | SEE REMARKS | MIXED | −54,862 | −$6.17M |
| 2025-03-31 | Bhatnagar Anish | CHIEF EXECUTIVE OFFICER | MIXED | −175,286 | −$40.90M |
| 2025-03-31 | Michael F. Huang | Sr. VP of Clinical Development | MIXED | −4,583 | −$794.33K |
| 2025-03-28 | Vivo Opportunity, LLC | 10%+ Owner | Sell | −1,833,557 | −$124.45M |
| 2025-01-23 | Michael F. Huang | Sr. VP of Clinical Development | A | +6,400 | — |
| 2025-01-23 | James H Mackaness | CHIEF FINANCIAL OFFICER | A | +14,500 | — |
| 2025-01-23 | Kristen Yen | SEE REMARKS | A | +6,400 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Vivo Opportunity, LLC | 10%+ Owner | 4,791,851 | $254.02M |
| Andrew Sinclair | Director | 1,201,507 | $63.69M |
| James H Mackaness | CHIEF FINANCIAL OFFICER | 131,763 | $6.98M |
| William G Harris | Director | 19,392 | $1.03M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SLNO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.